HC Wainwright Has Positive Outlook for AGIO FY2026 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research report issued on Friday, November 6th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings per share of ($5.58) for the year, up from their prior estimate of ($6.05). HC Wainwright has a “Buy” rating and a $62.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.12) EPS, FY2027 earnings at ($3.86) EPS, FY2028 earnings at ($1.84) EPS, FY2029 earnings at ($0.07) EPS and FY2030 earnings at $2.01 EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.15. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The company had revenue of $55.39 million for the quarter, compared to analyst estimates of $51.65 million.

A number of other analysts also recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Truist Financial dropped their target price on shares of Agios Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating for the company in a report on Friday. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. Bank of America boosted their price target on Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Finally, Citigroup boosted their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.12.

Agios Pharmaceuticals Stock Up 6.7%

Shares of AGIO opened at $31.38 on Tuesday. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00. The company has a 50-day simple moving average of $33.23 and a 200-day simple moving average of $31.78. The company has a market capitalization of $1.87 billion, a PE ratio of -4.97 and a beta of 0.66.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $239,582,000. Assenagon Asset Management S.A. increased its position in Agios Pharmaceuticals by 1,714.6% during the third quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock worth $62,723,000 after buying an additional 1,782,457 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth $47,800,000. Dimensional Fund Advisors LP increased its position in Agios Pharmaceuticals by 14.7% during the first quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock worth $38,940,000 after buying an additional 147,273 shares in the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth $24,828,000.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 7,866 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at $2,059,570.05. This trade represents a 12.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 9,855 shares of company stock valued at $371,112 in the last quarter. 5.40% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments.

Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.

Founded in 2008, Agios initially built a research portfolio in cancer metabolism before shifting its focus to rare genetic diseases.